Navigation Links
Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
Date:9/14/2010

SAN DIEGO, Sept. 14 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that new data from its North American and European fidaxomicin Phase 3 clinical trials in patients with Clostridium difficile infection (CDI) was presented at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

"Patients with CDI often have persistent infections or develop new infections during the course of CDI treatment and are often administered concomitant antibiotics. Although clinically necessary the use of concomitant antibiotics has a deleterious effect on outcomes of cure, recurrence and global cure. Compared to vancomycin therapy, fidaxomicin blunts these negative effects by significantly lowering recurrences and increasing global cure of patients," said Pedro Lichtinger, Optimer's President and Chief Executive Officer.  "The additional data presented suggest fidaxomicin has the potential to become the product of choice for CDI, if approved."

Kathleen M. Mullane, D.O., Pharm. D., an investigator from the University of Chicago, Department of Medicine, Section of Infectious Diseases, in Illinois, presented combined data from Optimer's two Phase 3 trials indicating that the use of concomitant antibiotics is a significant risk factor for a negative CDI treatment outcome.  Many patients with CDI have persistent infections or develop new infections during the course of CDI treatment making concomitant antibiotics clinically necessary and common.  Overall, 34% of subjects received antibiotics in addition to fidaxomicin a
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
2. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
3. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
4. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
7. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
8. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
9. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
10. Stemedica Announces Completion of Clinical Stem Cell Master Bank
11. DATATRAK International, Inc. Announces Initial Equity Research Coverage by Zacks Investment Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... , March 26, 2015 ... a global clinical research organization , ... a definitive agreement to acquire all of ... ("QSI"), a leading provider of specialized pharmacovigilance ... to the collection, detection, assessment, monitoring, and ...
(Date:3/26/2015)... the popular news television program that airs in numerous markets ... actor James Earl Jones, has announced that it will address ... Botany is commonly described as the scientific study of plants, ... complicated than that. Scientists and other professionals study a wide ... bacteria known to man to the largest trees that grow ...
(Date:3/26/2015)... WriteResult, a premier provider of ePRO ... University’s School of Public Health and New Haven Farms ... 4 month-long project. The goal of the study was ... with free access to fresh produce and nutrition education ... like high blood pressure, diabetes and weight gain. Patients ...
(Date:3/25/2015)... Agnition announced today that it will ... airing for the first time at 7:30 a.m. CST ... will explore the extremely important role soil microbes perform ... patented Microbial Catalyst™ technology that enhances soil and plant ... will air again on April 28. , A biochemist ...
Breaking Biology Technology:PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2
... Vicus Therapeutics, LLC, an,oncology-focused, clinical-stage, biopharmaceutical ... Clinical Research and Development, is,scheduled to present ... Tri-Conference on March 28st at 1:35 p.m. ... San Francisco. Dr. Rao will focus on,considerations ...
... to HistoRx AQUA(R) ... for tissue biomarker analysis-, NEW HAVEN, Conn., March ... a three-year agreement with Eli Lilly and Company,(NYSE: ... tissue biomarker,analysis widely available to Lilly researchers and clinicians ...
... company on track for Phase I/II trial ... ... Genetics Inc.,(TSX: SBS), a biotechnology company developing a portfolio of therapeutic,proteins ... toxicology study in animals to demonstrate the safety and,comparability of its ...
Cached Biology Technology:HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership 2HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership 3SemBioSys initiates toxicology study for safflower-produced insulin 2SemBioSys initiates toxicology study for safflower-produced insulin 3
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 ... fraud case conviction losses. This figure accounts for a ... according to The Nilson Report, exceeds $11 billion globally. ... tool after a crime has occurred. Investor Mark ... polygraph expert Joe Paolella partnered to administer ...
(Date:3/20/2015)... OXFORD, Conn. , March 20, 2015 ... "Company"), a biometric authentication company focused on the growing ... Wocket® smart wallet is one of the products featured ... today, March 20th at 11:00 PM EST on the ... travels to Las Vegas , site ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... at the Oregon National Primate Research Center at Oregon ... gene that appears to control how stem cells become ... implications for the study of Parkinson's disease, brain and ... might be combated by replacing lost or damaged brain ...
... that produce bird feathers have been visualized and analyzed for ... journey that may ultimately shed light on human organ regeneration. ... the journal Nature, was performed by a group of prominent ... University of Southern California. , "What we found is that ...
... team of scientists is proposing that endangered California condors raised ... so that the birds can once again feast on the ... , The researchers from Stanford University and four other institutions ... early condors and their potential prey. Writing in the Nov. ...
Cached Biology News:OHSU discovery sheds light into how stem cells become brain cells 2USC researchers track down the stem cells that create feathers 2USC researchers track down the stem cells that create feathers 3Seal rookeries could provide a reliable food source for endangered California condors, study finds 2Seal rookeries could provide a reliable food source for endangered California condors, study finds 3Seal rookeries could provide a reliable food source for endangered California condors, study finds 4Seal rookeries could provide a reliable food source for endangered California condors, study finds 5
...
... designed to allow neomycin/kanamycin selection in ... loxP-PGK-gb2-neo-loxP template encodes the neomycin/kanamycin resistance ... (gb2) for expression of kanamycin resistance ... (PGK) for expression of neomycin resistance ...
... inch long PYREX NMR tubes are made from ... valves, and vacuum racks. They are designed for ... 500MHz. They have an O.D. of 4.97 + ... These NMR tubes can be used with the ...
... TProfessional Thermocycler combines top performance with exquisite ... high speed and unparalleled temperature uniformity. The ... programming in a spreadsheet or alternatively in ... Lid opens on the push of a ...
Biology Products: